Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

C19-IG · C19

Plasma-derived product · Acts on SARS-CoV-2 spike protein · developed by Grifols Therapeutics LLC

Phase 3 Most advanced trial (none active)
GRFS Developer
1 Registered trials

What is C19-IG?

C19-IG is an anti-COVID-19 immune globulin (human) 20% preparation.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
C19
Drug type
Plasma-derived product
Targets
SARS-CoV-2 spike protein
Mechanism
Acts on SARS-CoV-2 spike protein
Therapy area
Infectious disease
Developer
Grifols Therapeutics LLC (GRFS)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04847141 Phase 3 COVID-19 Terminated GRFS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

COVID-19

More from Grifols Therapeutics LLC

albumin human, USP FDA approved Antithrombin III FDA approved factor VIII / von Willebrand factor FDA approved Alpha-1 Phase 3 Fibrin Sealant Grifols Phase 3 GRF312 Phase 2 Human Plasma-Derived Fibrinogen Concentrate Phase 1/2 IVIG-PEG Phase 3 plasma-derived FVIII/VWF concentrate Phase 4

Sources

Updated Oct 11, 2026. Something wrong or missing? Report it on the GRFS page.

Follow GRFS, the company behind C19-IG

See GRFS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

GRFS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.